Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
1994-12-12
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0959-8049
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
30A
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1044-5
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:7946574-Adult,
pubmed-meshheading:7946574-Aged,
pubmed-meshheading:7946574-Carcinoma, Squamous Cell,
pubmed-meshheading:7946574-Female,
pubmed-meshheading:7946574-Head and Neck Neoplasms,
pubmed-meshheading:7946574-Humans,
pubmed-meshheading:7946574-Male,
pubmed-meshheading:7946574-Middle Aged,
pubmed-meshheading:7946574-Pyrimidines
|
| pubmed:year |
1994
|
| pubmed:articleTitle |
A phase II study of piritrexim in patients with advanced squamous cell carcinoma of the head and neck.
|
| pubmed:publicationType |
Letter,
Clinical Trial,
Clinical Trial, Phase II
|